NLRP3 and non-small cell lung carcinoma: Even though limited number of non-malignant pulmonary disease patients in our study, higher CD3+NLRP3+ MFI in early-stage NSCLC patients compared to non-malignant pulmonary disease patients probe the possibility of these PBMCs protein expressions as a biomarker to discriminate between those 2 conditions.